Insider Selling: Artivion (NYSE:AORT) SVP Sells $57,524.26 in Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 1,513 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $38.02, for a total value of $57,524.26. Following the transaction, the senior vice president directly owned 40,408 shares of the company’s stock, valued at approximately $1,536,312.16. This represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Trading Down 1.6%

Shares of AORT stock opened at $37.87 on Friday. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of 189.36 and a beta of 1.60. The stock has a 50-day moving average of $41.24 and a 200-day moving average of $42.88.

Artivion (NYSE:AORT) last released its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AORT. Invesco Ltd. increased its stake in Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Artivion in the fourth quarter valued at approximately $746,000. Susquehanna Portfolio Strategies LLC increased its position in shares of Artivion by 21.5% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock valued at $1,849,000 after acquiring an additional 7,186 shares during the last quarter. Occudo Quantitative Strategies LP bought a new stake in Artivion during the fourth quarter worth $248,000. Finally, Millennium Management LLC boosted its position in Artivion by 1.0% in the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after purchasing an additional 893 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

AORT has been the topic of a number of recent analyst reports. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Citizens Jmp raised their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Canaccord Genuity Group lowered their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Needham & Company LLC reissued a “buy” rating and set a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Finally, Stifel Nicolaus set a $55.00 price objective on shares of Artivion in a report on Thursday. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.47.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.